Table 1 Baseline patient demographics (n=27)

From: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

Parameter

No. (%)

Median age, years (range)

58 (33–72)

Gender

 Male

18 (67)

 Female

9 (33)

ECOG performance status

 0

13 (48)

 1

12 (45)

 2

2 (7)

Primary tumour site

 Colorectal

21 (78)

 Gastric

4 (15)

 Pancreas

2 (7)

Histology

 Adenocarcinoma

26 (96)

 Squamous cell carcinoma

1 (4)

Median number of metastatic lesions (range)

3 (1–5)

Prior treatment

 Surgery

23 (85)

 Radiotherapy

6 (22)

No. of prior chemotherapy regimens a

 0

5 (19)

 1

13 (48)

 2

3 (11)

 >2

6 (22)

  1. ECOG=Eastern Cooperative Oncology Group; 5-FU=5-fluorouracil.
  2. aAll regimens, including 5-FU.